BioSpace News Archive

OncoPep, Inc. announced a licensing agreement with MANA Therapeutics for use of its EDIFY™ platform for the development of an autologous multi-tumor antigen adoptive T cell therapy for the treatment of multiple myeloma and solid tumors, as an additional T cell focused immunotherapeutic for its product pipeline.

Bile duct cancer or cholangiocarcinoma is cancer of the biliary system. This system lies under the liver and is responsible for production of waste bile as part of the body’s normal recycling processes.

Diagnostic imaging is a technique used to conduct a wide range of non-invasive imaging tests for diagnosing and monitoring diseases or injuries by the way of generating images that represent internal structures and organs in the patient’s body.

The global knee cartilage repair market is expanding due to rise in the global geriatric population and lifestyle changes coupled with growing awareness about sports and outdoor activities among the younger as well as elderly generation.

The process of chaining or modification of biological molecules by conjugation with non-immunogenic polymer and nontoxic polyethylene glycol to improve or modify the physicochemical property of molecule is known as PEGylation.

Soft tissue repair process is defined as replacement of damaged or injured tissue with healthy tissues. The process of replacement is highly surgical and present success rate is considerably low.

Patients can now schedule appointments and receive remote medical care through a mobile teleconsultation solution

NanoViricides, Inc., reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2020 with the Securities and Exchange Commission on Tuesday, October 12, 2020.

Prof. Hagop M. Kantarjian, M.D., Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, has joined KAHR’s clinical advisory board.

Annovis Bio Inc., a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases, announced its business highlights for the third quarter ended September 30, 2020.